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Abstract
Background: Extensive-disease small-cell lung cancer (ED-SCLC) is characterized by rapid progression and relapse,
despite high initial response rates to chemotherapy. The primary objective of this trial was to demonstrate the non-
inferiority of amrubicin and cisplatin (AP) combination therapy compared with the standard first-line regimen of
etoposide and cisplatin (EP) for previously untreated ED-SCLC in a Chinese population. When non-inferiority was
verified, the objective was switched from non-inferiority to superiority.
Methods: From June 2008 to July 2010, 300 patients were enrolled and randomly assigned at a 1:1 ratio to AP and
EP groups. AP-treated patients received cisplatin (60 mg/m2, day 1) and amrubicin (40 mg/m2, days 1–3) once
every 21 days. EP-treated patients received cisplatin (80 mg/m2, day 1) and etoposide (100 mg/m2, days 1–3) once
every 21 days. Treatment was continued for four to six cycles, except in cases of progressive disease or toxicity, and
patient refusal.
Results: Median overall survival (OS) for AP vs. EP treatment was 11.8 vs. 10.3 months (p = 0.08), respectively,
demonstrating non-inferiority of AP to EP (AP group: 95 % confidence interval for hazard ratio 0.63–1.03 months).
Median progression-free survival and overall response rates for AP vs. EP groups were 6.8 vs. 5.7 months (p = 0.35)
and 69.8 % vs. 57.3 %, respectively. Drug-related adverse events in both groups were similar, with neutropenia
being the most frequent (AP 54.4 %; EP 44.0 %). Leukopenia, pyrexia, and fatigue were more prevalent in the AP
group, but all were clinically reversible and manageable.
Conclusions: AP therapy demonstrated non-inferiority to EP therapy, prolonging OS for 1.5 months, but this
difference was not statistically significant; thus we propose AP as a promising treatment option for ED-SCLC in
China.
Trial registration: This trial was registered on 10 April 2008 (ClinicalTrials.gov NCT00660504).
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Background
Lung cancer is the most common cancer in China, with
new cases estimated at a rate of 46.08 per 100,000 in
2010 [1]. Small-cell lung cancer (SCLC) is the most ag-
gressive subtype, accounting for approximately 15–20 %
of lung cancers and is classified as limited or extensive
disease [2, 3]. Extensive-disease (ED)-SCLC accounts for
60–70 % of all SCLC cases and is characterized by rapid
progression [4]. SCLC is chemosensitive and combin-
ation chemotherapy is effective for cases of untreated
ED-SCLC, but only 15–20 % of patients achieve a
complete response; most eventually relapse, and the me-
dian survival time (MST) from diagnosis is only 9–10
months. Combination chemotherapy using a platinum-
based drug plus etoposide is the most commonly used
regimen for first-line treatment for metastatic SCLC,
and etoposide plus cisplatin (EP) therapy has been the
global standard since the mid-1980s [5–7]. Over the
last two decades, many regimens of targeted therapies
and newer chemotherapeutic agents have been trialed
[8–16], but the outcome for SCLC patients has not
been significantly improved.
Amrubicin is a synthetic anthracycline and a potent
topoisomerase II inhibitor. Its acute toxicity is qualita-
tively similar to that of doxorubicin, but amrubicin
shows almost no heart damage at cumulative doses
[17, 18] and does not exhibit the chronic cardiotoxic
effects (e.g., congestive heart failure) in rabbits and
dogs that are observed with doxorubicin [19–21].
In 2002, amrubicin was approved for NSCLC and
SCLC treatment in Japan, and shows promising efficacy
as a single agent therapy. In a phase II study, 33 previ-
ously untreated ED-SCLC patients received amrubicin
monotherapy with a dose schedule of 45 mg/m2 on days
1–3 every 3 weeks. The overall response rate (ORR) was
75.8 %, the MST was 11.7 months, and the 1-year sur-
vival rate was 48.5 % [22]. Amrubicin also showed good
efficacy when administered in combination with plat-
inum. In a phase I/II study in 41 previously untreated
patients, the ORR was 87.8 %, the MST was 13.6 months,
and the 2-year survival rate was 17.6 % [23]. Further
phase II studies have been conducted in Western popu-
lations with initial ED-SCLC. In one such study, 30 pa-
tients received amrubicin with cisplatin. The ORR was
76.7 % and the MST was 11.1 months [24]. A phase II
study of amrubicin as second-line therapy in 75 patients
with platinum-refractory SCLC enrolled from the US
and EU revealed an ORR of 21.3 %, and median
progression-free survival (PFS) and overall survival (OS)
times of 3.2 months and 6.0 months, respectively, in par-
allel with an acceptable safety profile [25]. Similarly, in
another phase II study conducted in Western patients
(n = 76) in which amrubicin was compared with topote-
can, amrubicin achieved a significantly higher ORR of
44 % and had a similar safety profile to topotecan [26].
A recent second-line phase III trial in 637 patients re-
cruited from the US, Europe, and Australia showed that
amrubicin did not improve survival, but that it had dem-
onstrable activity and a good safety profile compared
with that of topotecan [27].
Here, we report the results of multicenter, open-label,
randomized phase III trial comparing amrubicin and cis-
platin (AP) therapy with EP therapy in previously
untreated Chinese ED-SCLC patients. The primary ob-
jective of this trial was to demonstrate non-inferiority in
OS, and when non-inferiority was verified, the objective
was switched from non-inferiority to superiority.
Methods
Study design and patients
This multicenter, randomized, phase III, open-label study
involved 17 Chinese hospitals. Patients with histologically
or cytologically documented SCLC were eligible for inclu-
sion. Each patient was required to meet the following cri-
teria: extensive-stage disease; no prior therapy for the
primary lesion; a measurable lesion; Eastern Cooperative
Oncology Group performance status (ECOG PS) of 0 or
1; age ≥18 years; adequate hematological function (white
blood cells ≥4,000–10,000/μL, neutrophils ≥2,000/μL,
blood platelets ≥100,000/μL, hemoglobin ≥9.5 g/dL); ad-
equate hepatic function (aspartate aminotransferase and
alanine aminotransferase ≤2.5-fold upper limit of normal,
serum bilirubin <1.5-fold upper limit of normal, adequate
renal function (serum creatinine ≤ upper limit of normal);
minimum life expectancy ≥3 months; no electrocardio-
gram abnormality requiring treatment; left ventricular
ejection fraction (LVEF) ≥55 %; and provision of written
informed consent. Patients with known brain metastasis
were eligible if they were asymptomatic and had stable
disease without any therapy.
Patients were excluded if they had received any previous
therapy for the primary lesion, pleural effusion requiring
drainage, superior vena cava syndrome, gastric or duo-
denal ulcers, severe heart disease, severe renal disease, ac-
tive concomitant malignancy, symptomatic pneumonitis,
or pulmonary fibrosis. Pregnant or nursing women were
also excluded.
The protocol was conducted in accordance with the
Declaration of Helsinki, and was approved by the institu-
tional ethics committee at each center (a list of ethics
committees is provided in the Supporting Information
[Additional file 1]), and all patients initially provided
written informed consent. The study was registered at
ClinicalTrials.gov (NCT00660504).
Randomization
Patients who met the entry criteria were registered and
randomly assigned to a treatment centrally via an
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interactive web response system. Patients were assigned at
a 1:1 ratio to AP or EP treatment groups using a
computer-generated randomization list. Central random
assignment by dynamic allocation to the AP or EP group
was stratified according to institution, sex, and ECOG PS
(0 or 1), and was balanced for stratification factors using
the Pocock and Simon dynamic balancing procedure [28].
Treatments
Treatment commenced within 14 days of randomization.
Based on the result of a Japanese Phase I/II study [23],
patients in the AP group received cisplatin (60 mg/m2,
day 1) and amrubicin (40 mg/m2, days 1–3) once every
21 days. Those in the EP group received the Chinese
standard regimen of cisplatin (80 mg/m2, day 1) and eto-
poside (100 mg/m2, days 1–3) once every 21 days. Pa-
tients were treated for 4–6 cycles until the occurrence of
progressive disease or toxicity, or patient refusal. Dose
modifications were allowed in cases of toxicity. The
amrubicin dose was reduced in increments of 5 mg/m2/
day for grade 3 or 4 neutropenic fever or sepsis, grade 4
neutropenia lasting ≥4 consecutive days, grade 4
thrombocytopenia, or any grade 3 or 4 nonhematologic
toxicity except nausea or vomiting; the etoposide dose was
reduced in increments of 20 mg/m2/day for patients exhi-
biting the same symptoms. The cisplatin dose was reduced
in increments of 20 mg/m2/day for serum creatinine escal-
ation, grade 3 nonhematologic toxicity except nausea or
vomiting, and neuropathic disorders. Once a dose reduc-
tion had been implemented, the dose could not be re-
escalated. Following treatment, prophylactic cranial irradi-
ation (PCI) was offered to patients who had achieved
complete response or good partial response.
Endpoints
The primary endpoint was OS, and the secondary end-
points were PFS and investigator-determined ORR.
Tumor response was evaluated using Response Evalu-
ation Criteria In Solid Tumors version 1.0. The antitu-
mor effect was evaluated by computed tomography
every two cycles after the first injection. Stable disease
was defined as a case that met the defined criteria for
stable disease at least twice after study entry at a mini-
mum interval of 6 weeks. Adverse events (AEs) were
graded according to the Common Terminology Criteria
for AEs version 3.0; no cutoff period was defined for
treatment-emergent AEs.
Statistical analysis
An intention-to-treat (ITT) analysis, which excluded one
patient who withdrew consent before the first adminis-
tration, was used for efficacy and safety analyses. Patient
sample size was determined by taking into account the
enrollment period of 1.5 years and the commencement
of follow-up at 1.5 years after the last patient enrollment,
with a two-sided significance value of 5 % (95 % confi-
dence interval (CI) for evaluation). MSTs of 13.6 months
[23] and 9.4 months [22] were assumed for AP and EP
therapy of ED-SCLC, respectively. Non-inferiority was
defined by the upper limit of the 95 % CI for the hazard
ratio (HR) being set at <1.25. Non-inferiority was estab-
lished with >99 % power for 300 patients (150 per group)
in total. Superiority could be determined if the upper limit
of the 95 % CI for HR was <1, and could be confirmed fol-
lowing validation of non-inferiority. Under these condi-
tions, superiority could also be calculated with a power of
more than 80 %. The point estimate and 95 % CI of the
HR for the AP group relative to the EP group were calcu-
lated for OS and PFS with the Cox proportional hazards
model using the following factors (excluding the clinical
trial institution) defined during dynamic randomization:
treatment; PS at baseline; and sex.
Results
Patients
From June 2008 to July 2010, 300 patients were enrolled
and randomly assigned at a 1:1 ratio to the AP and EP
groups (Fig. 1). One patient withdrew informed consent
before administration and was excluded from the ITT
analysis. Therefore, 299 patients (AP group, n = 149; EP
group, n = 150) were included in the ITT analysis of effi-
cacy and safety. The baseline demographic and disease
characteristics of the patients are listed in Table 1. There
was no difference in patient baseline demographics be-
tween the groups.
Treatment delivery
The median numbers of treatment cycles were 4.6 in the
AP group and 4.5 in the EP group; 118 patients in the
AP group and 110 in the EP group completed four to six
cycles. During the study period, 90 patients in the AP
group and 73 patients in the EP group received a dose
reduction or had their treatment schedule prolonged.
Although eight patients in the AP group and one in the
EP group needed two dose level reductions (amrubicin;
30 mg/m2/day, etoposide; 60 mg/m2/day), almost all pa-
tients received >80 % of the planned dosage. Thirty-one
patients in the AP group and 41 in the EP group were
withdrawn from treatment, mainly because of patient re-
quest (AP group, nine; EP group, 11) and disease pro-
gression (AP group, six; EP group, 13).
Efficacy
Survival
The primary endpoint of OS is shown in Fig. 2. The final
survival follow-up point was defined as 1.5 years after
enrollment of the last patient. The median OS (95 %
two-sided CI) was 11.8 months (range, 11.0–
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12.6 months) in the AP group and 10.3 months (range,
9.2–12.0 months) in the EP group. Therefore, the AP
group demonstrated non-inferiority to the EP group, in
as much as the HR was 0.81 and the 95 % CI was 0.63–
1.03, which met the criteria for non-inferiority. Add-
itionally, regarding the analysis for superiority, the AP
group showed an improved median OS that was
1.5 months longer than that of the EP group, but this
difference was not statistically significant (p = 0.08). The
1-year survival rates in the AP vs. EP groups were
48.6 % (95 % CI 40.3–56.4) vs. 41.9 % (95 % CI 34.0–
49.7), respectively.
PFS
PFS was a secondary endpoint in this study (Fig. 3). The
median PFS was 6.8 months (range, 6.1–7.4 months) in the
AP group and 5.7 months (range, 5.1–6.9 months) in the
EP group (HR for AP 0.88; 95 % CI 0.66–1.16) but these
differences were not statistically significant (p = 0.35).
ORR
ORRs were 69.8 % (104/149) in the AP group and
57.3 % (86/150) in the EP group. Five complete and 99
partial responses were achieved in the AP group, while
the EP group demonstrated three complete and 83 par-
tial responses. The ORR in the AP group was signifi-
cantly improved compared with that in the EP group
(95 % CI 1.7–23.3 %).
Assessed for eligibility
and
Randomized  (n = 300)
• Allocated to intervention (n = 149) 
• Received allocated intervention (n = 149)
• Did not receive allocated intervention (n = 0) 
• Discontinued intervention (n = 150)
• Lost to follow-up after discontinuation of 
intervention (n = 0)
• Analyzed (n = 149) 
• Excluded from analysis (n = 0)
• Allocated to intervention (n = 151) 
• Received allocated intervention (n = 150) 
• Did not receive allocated intervention (due to  
withdrawal of consent) (n = 1) 
• Analyzed (n = 150)
• Excluded from analysis (n = 0)
• Discontinued intervention (n = 149)
• Lost to follow-up after discontinuation of 























Fig. 1 Patient flowchart. AP, amrubicin/cisplatin; EP, etoposide/cisplatin
Table 1 Patient characteristics
AP group EP group
Number of patients 149 150
Sex
Male 114 (76.5 %) 113 (75.3 %)
Female 35 (23.5 %) 37 (24.7 %)
Median age, years (SD)a 58.0 (13.0) 59.0 (13.0)
ECOG PS
0 42 (28.2 %) 32 (21.3 %)
1 107 (71.8 %) 118 (78.7 %)
Stage
IIIB 3 (2.0 %) 9 (6.0 %)
IV 146 (98.0 %) 141 (94.0 %)
Metastasisb 148 (99.3 %) 144(96.0 %)
Lung 18 (12.1 %) 22 (14.7 %)
Bone 60 (40.3 %) 65 (43.3 %)
Brain 30 (20.1 %) 17 (11.3 %)
Liver 37 (24.8 %) 41 (27.3 %)
Other 82 (55.0 %) 78 (52.0 %)
Data are number (%) except amedian (SD)
bSeveral patients had metastases to multiple sites
AP amrubicin/cisplatin, EP etoposide/cisplatin, SD standard deviation, ECOG PS
Eastern Cooperative Oncology Group
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Number at risk
AP 149 142 133 108 71 47 35 23 15 10 7 5 4 1 1 0
EP 150 147 129 89 62 38 27 19 9 7 5 5 3 2 0 0
Time (months)
Median, months 
AP 11.8 (95% CI 11.0–12.6)
EP 10.3 (95% CI 9.2–12.0)
(HR 0 81; 95% CI 0 63–1 03)
OS 6 months 12 months 18 months
AP 89.3% 48.6% 24.6%
















Fig. 2 Cumulative survival rate of patients. AP group (n = 149; black triangles), EP group (n = 150; red circles) (ITT population). AP, amrubicin/cisplatin;
CI, confidence interval; EP, etoposide/cisplatin; HR, hazard ratio; OS, overall survival
Number at risk
AP 149 112 56 21 11 8 7 7 5 4 2 1 1 1 1 0























AP 6.8 (95% CI 6.1–7.4)
EP 5.7 (95% CI 5.1–6.9)
(HR 0.88; 95% CI, 0.66–1.16)
Fig. 3 Progression-free survival of patients. AP group (n = 149; black triangles), EP group (n = 150; red circles) (ITT population). AP, amrubicin/cisplatin;
CI, confidence interval; EP, etoposide/cisplatin; HR, hazard ratio; ITT, intent-to-treat
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Safety
The AEs observed during this study are listed in Table 2.
The most common AE of grade 3 or worse in both
groups was hematologic toxicity: in the AP and EP
groups, neutropenia occurred in 54.4 % (81/149) and
44.0 % (66/150) of patients, respectively, leukopenia in
34.9 % (52/149) and 19.3 % (29/150), respectively, and
thrombocytopenia in 16.1 % (24/149) and 7.3 % (11/
150), respectively. The AEs with absolute >10 % differ-
ences between the two groups (AP vs. EP) were pyrexia
(18.8 vs. 8.0 %), fatigue (18.1 vs. 7.3 %), and diarrhea
(16.8 vs. 8.7 %). These incidences were higher in the AP
group, but most cases recovered and the AEs were man-
ageable for both groups. Six patients in the AP group
had febrile neutropenia, but no cases were observed in
the EP group.
Regarding cardiotoxicity, there was one case of ven-
tricular arrhythmia and one of supraventricular tachyar-
rhythmia in the AP group and one case of myocardial
ischemia in the EP group, all of which were reversible.
The LVEF at baseline in the AP group was 65.8 ± 5.9 %
(mean ± SD), while that post-treatment was 63.9 ± 5.2 %;
hence, AP therapy had no clinically important effect. Se-
vere AEs (SAEs) occurred in 21 patients in the AP group
and eight in the EP group, but most were reversible. Al-
though frequent SAEs in the AP group were grade 3–4
neutropenia and leukopenia, these were successfully
treated with granulocyte colony-stimulating factor (G-
CSF). Treatment-related death occurred in three patients
(one with granulocytopenia, one with hypokalemia and
cerebral infarction, and one with grade 4 myelosuppres-
sion) in the AP group and one (with acute cerebral in-
farction) in the EP group.
Discussion
This is the first reported phase III study to compare AP
therapy with EP therapy for previously untreated ED-
SCLC. We demonstrated non-inferiority but not super-
iority of AP therapy to EP therapy, with a prolonged
median OS of 1.5 months. It is conceivable that the ef-
fect of post-study treatment was minor, because the dif-
ference of median PFS between two groups was
1.1 months. In fact, approximately 75 % of the patients
did not receive post-study treatment.
The toxicity of AP therapy was also tolerable, despite
AE incidences in the AP group being higher than in the
EP group. The most common severe toxicity associated
with amrubicin was myelosuppression, but most cases
were reversible. The rate of grade 3 or worse neutro-
penia was within the range of previous reports (95.1 %
and 84.8 %) [22, 23], and the degree of myelosuppression
and its risk of secondary serious infection and sepsis was
manageable with protocol-specific dose reductions,
treatment delays, and prophylactic use of G-CSF and an-
tibiotics. The rate of febrile neutropenia in the AP group
(4.0 %) was considerably lower than observed in a previ-
ous Japanese study by Satouchi et al. [29]. Although the
reasons for this are not clear, almost 80 % of patients
Table 2 Hematological and non-hematological adverse events
AP group (n = 149) EP group (n = 150)
Total ≥Grade 3 Total ≥Grade 3
Events (CTCAE v3.0) n % n % n % n %
Patients with one or more adverse events 149 100 - - 148 98.7 - -
Anemia 48 32.2 10 6.7 48 32.0 10 6.7
Hemoglobin decreased 49 32.9 16 10.7 50 33.3 8 5.3
Leukopenia 97 65.1 52 34.9 85 56.7 29 19.3
Neutropenia 99 66.4 81 54.4 85 56.7 66 44.0
Thrombocytopenia 54 36.2 16.1 40 26.7 11 7.3
Constipation 32 21.5 0 25 16.7 0
Diarrhea 25 16.8 3 2.0 13 8.7 1 0.7
Gastrointestinal disorder 22 14.8 3 2.0 26 17.3 1 0 · 7
Nausea 72 48.3 6 4.0 70 46.7 4 2.7
Vomiting 63 42.3 7 4.7 63 42.0 6 4.0
Fatigue 27 18.1 2 1.3 11 7.3 0
Pyrexia 28 18.8 1 0.7 12 8.0 0
Anorexia 60 40.3 2 1.3 50 33.3 5 3.3
Alopecia 31 20.8 1 0.7 20 13.3 0
Data are number (%)
AP amrubicin/cisplatin, EP etoposide/cisplatin
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received G-CSF, and there were no differences between
treatment groups in the use of G-CSF. This observation
may be explained by the suitable use of G-CSF. No clin-
ically significant LVEF reduction was found and there
was no evidence of cardiomyopathy, congestive heart
failure, or treatment-related cardiac mortality. While
three patients in the AP group and one in the EP group
died because of their treatment regimen, cancer chemo-
therapy is reported to be responsible for approximately
2–3 % of treatment-related deaths [30, 31]. Furthermore,
there was no correlation between the number of admin-
istered treatment cycles and the frequency of treatment-
related death risk in this study.
Recently, the West Japan Thoracic Oncology Group
reported sequential chemotherapy consisting of three cy-
cles of irinotecan and cisplatin followed by three cycles
of amrubicin for previously untreated ED-SCLC [32].
This report was a phase II study but demonstrates the
effective use of amrubicin in previously untreated SCLC.
Despite the high incidence of toxicity, amrubicin dem-
onstrated sufficient efficacy compared with approved
drugs for the treatment of SCLC. Its efficacy and alter-
nate mechanism of action make it a potential candidate
for treatment of this disease. More effective use of the
evidence for amrubicin in the treatment of Chinese
SCLC patients is needed.
Conclusions
In our study, the OS of previously untreated Chinese pa-
tients with ED-SCLC following AP therapy was non-
inferior to EP therapy, prolonging OS for 1.5 months. This
result suggests that while AP therapy has sufficient effi-
cacy, EP therapy is still the gold standard for first-line
treatment of SCLC. Among the investigational drugs,
amrubicin shows promise as a therapy for SCLC, and fur-
ther studies are required to identify its most effective use.
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